In point of fact, F16-IL-2 treatment of acute myeloid leukemia (AML) relapsed patients after HSCT led to a massive accumulation of lymphocytes in the bone marrow and CD56+CD16+ NK cells represented the most prominent increment, besides γδT and CD8+ T cells (52). The gene discussed is CD8A; the disease is acute myeloid leukemia.